一项使用中药Coriolus Versicolor改善晚期癌症患者生活质量的随机、双盲、安慰剂对照临床试验。受试者将被随机分为治疗组或安慰剂组，为期6个月。
适应症：Cancer、Palliative Care
入组条件
纳入标准
- Diagnosed with advanced cancer according to the definition from American Cancer Society;
- According to the experience of the doctor, by using Palliative Prognostic Index (score\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years;
- Abbreviated mental test (AMT) score of 6 or above;
- Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient);
- Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes/patterns, syndrome of "damp heat spleen" and "spleen deficiency with water stop" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms).
排除标准
- Patients with a history of allergy to traditional Chinese medicine or Yunzhi;
- Patients who required nasal feeding or difficulty swallowing;
- Patients with comatose/semi-conscious, cognitively impaired with dementia/confusion, physically too ill with extremely poor general condition, or there was a language barrier.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。